Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-12
    E.g., 2018-11-12

Articles

173693 items
12:00 AM, Oct 10, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

GEM 91 antisense compound: Will start Phase IB/II trial

Hybridon Inc., Worcester, Mass.   Product: GEM 91 antisense compound   Indication: HIV-1 infection and AIDS   Status: Will start Phase IB/II trial in 60 patients in the U.S. and France, in October and November respectively, to assess...
12:00 AM, Oct 03, 1994  |  BC Week In Review | Company News  |  Sales & Marketing

Bio-Technology General sales and marketing update

BTGC's partner, The Ferring Group, began selling BTGC's human growth hormone in the Netherlands. The Iselin, N.J., company also announced that its hGH received marketing approval in Sweden. Ferring has marketing rights to hGH in...
12:00 AM, Oct 03, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Meridian Diagnostics regulatory update

The Cincinnati company received FDA approval to market its fourth ImmunoCard product, to diagnose Mycoplasma pneumoniae, an organism that causes severe respiratory distress. The test, a credit card-sized enzyme immunoassay that produces results in five...
12:00 AM, Oct 03, 1994  |  BC Week In Review | Company News  |  Deals

Vertex deal

VRTX (Cambridge, Mass.) entered into a clinical development program with BASF's Ravizza Farmaceutici S.p.A (Italy) subsidiary for compounds to treat inherited hemoglobin disorders. The companies initially will share data generated in their respective clinical...
12:00 AM, Oct 03, 1994  |  BC Week In Review | Company News  |  Deals

Vical deal

VICL said the total value of the deal, excluding royalties, could exceed $50 million. Vical Inc. (VICL)   VICL (San Diego) entered into an agreement with Pasteur-Merieux covering the use of VICL's naked DNA technology for...
12:00 AM, Oct 03, 1994  |  BC Week In Review | Company News  |  Deals

Quidel deal

Byk Gulden (Germany) received an exclusive license to certain QDEL products to be sold in Poland by Byk's Byk Polska subsidiary. The agreement covers the San Diego company's allergy products and H. pylori test to...
12:00 AM, Oct 03, 1994  |  BC Week In Review | Company News  |  Deals

Biopharmaceutics deal

The Bellport, N.Y., company acquired from the Research Foundation of State University of New York at Stony Brook the rights to an antiviral compound that kills HIV and hepatitis B viruses. The compound contains ingredients...
12:00 AM, Oct 03, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Hyal Pharmaceuticals Corp. regulatory update

Hyal Pharmaceuticals Corp. (HYALF)   The Mississauga, Ontario, company's HYAL-CT1101 received approval under Canada's Emergency Drug Release program to treat actinic keratosis in immune suppressed patients. Actinic keratosis is a chronic precancerous skin condition that...
12:00 AM, Oct 03, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Liposome Tech regulatory update

The Committee on Proprietary and Medicinal Products of the European Union will review LTIZ's DOX-SL Stealth liposome product under the high technology List B concertation procedure. Under this route, a company is allowed to file...
12:00 AM, Oct 03, 1994  |  BC Week In Review | Company News  |  Deals

Interneuron deal

IPIC (Lexington, Mass.) completed its previously announced acquisition of Cardiovascular Pharmacology and Engineering Consultants (CPEC) for an undisclosed amount. CPEC is developing bucindolol, a beta blocker to treat heart failure. Bucindolol will begin a 3,000-patient...

Pages